GlyphAgo Repeat Dosing Shows Favorable Safety Profile
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 53 minutes ago
0mins
Source: Yahoo Finance
- Clinical Trial Results: GlyphAgo demonstrated a favorable safety and tolerability profile in the multiple ascending dose trial with healthy volunteers, with no liver-related adverse events observed, laying a solid foundation for its further development in generalized anxiety disorder patients.
- Pharmacokinetic Advantages: The seven-day dosing regimen achieved therapeutic exposures of agomelatine that are projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, significantly enhancing clinical applicability.
- Future Trial Plans: Seaport plans to initiate two parallel Phase 2 clinical trials in the second half of 2026, aimed at validating the efficacy and safety of GlyphAgo for patients with generalized anxiety disorder, potentially providing new treatment options for patients.
- Enhanced Bioavailability: In crossover trials, GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, with 10-fold lower pharmacokinetic variability across different doses, further demonstrating its potential in clinical applications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SPTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SPTX
Wall Street analysts forecast SPTX stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 17.880
Low
Averages
High
Current: 17.880
Low
Averages
High
About SPTX
Seaport Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Its product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder. It is also advancing Glyph2BLS (SPT-348 or Glyph 2-bromo-LSD), a novel, Glyphed oral prodrug of the non-hallucinogenic LSD analog 2-bromo-LSD, in preclinical studies for depressive disorders. GlyphAllo is designed to overcome the bioavailability limitations of allopregnanolone and be durable in MDD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GlyphAgo Repeat Dosing Shows Favorable Safety Profile
- Clinical Trial Results: GlyphAgo demonstrated a favorable safety and tolerability profile in the multiple ascending dose trial with healthy volunteers, with no liver-related adverse events observed, laying a solid foundation for its further development in generalized anxiety disorder patients.
- Pharmacokinetic Advantages: The seven-day dosing regimen achieved therapeutic exposures of agomelatine that are projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, significantly enhancing clinical applicability.
- Future Trial Plans: Seaport plans to initiate two parallel Phase 2 clinical trials in the second half of 2026, aimed at validating the efficacy and safety of GlyphAgo for patients with generalized anxiety disorder, potentially providing new treatment options for patients.
- Enhanced Bioavailability: In crossover trials, GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, with 10-fold lower pharmacokinetic variability across different doses, further demonstrating its potential in clinical applications.
See More
Seaport Therapeutics Raises $260 Million in Successful IPO
- Successful IPO Financing: Seaport Therapeutics completed an upsized IPO in May 2026, raising $260 million in gross proceeds, which will support the company's operations into 2029, reflecting strong market confidence in its neuropsychiatric drug development.
- Clinical Trial Progress: New data from the Phase 1 trial of GlyphAgoTM indicate that a seven-day dosing regimen can achieve therapeutic exposures at doses projected to avoid liver enzyme elevations, potentially reducing or eliminating the need for liver function testing, thereby enhancing patient safety.
- New Board Member Appointment: Dr. Sharon Mates has been appointed to Seaport's Board of Directors; she previously served as the Co-Founder and CEO of Intra-Cellular Therapies, bringing extensive industry experience that is expected to drive the company's strategic development in the neuropsychiatry field.
- Increased R&D Spending: Research and development expenses for Q1 2026 were $21.4 million, significantly up from $10.5 million in Q1 2025, primarily due to accelerated clinical development of GlyphAlloTM and GlyphAgoTM, reflecting the company's ongoing commitment to new drug development.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
Strong IPO Performance from Biotech Firms
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
See More
Hemab and Seaport Shares Surge on Strong IPO Debuts
- Hemab's Debut Performance: Hemab Therapeutics priced its IPO at $18 per share, opening at $27, reflecting a ~50% increase, and reaching $29.68 by 1:30 PM ET, indicating strong market confidence in its bleeding disorder treatments.
- Seaport's Stock Surge: Seaport Therapeutics also priced its IPO at $18, opening at $21, a ~17% rise, and climbing to $22.51 by 1:30 PM ET, showcasing investor optimism regarding its neuropsychiatric drug development.
- Significant Fundraising: The two companies collectively raised over $550 million through upsized IPOs, with Hemab expecting $301.5 million and Seaport $254.9 million, providing robust funding for future R&D and market expansion.
- Positive Market Reaction: The successful listings of both companies not only highlight the vitality of the biotech sector but also reflect investor confidence in new drug development, particularly driven by positive clinical trial results, potentially attracting more attention to this field.
See More
GlyphAgo Repeat Dosing Shows Favorable Safety Profile
- Clinical Trial Results: GlyphAgo demonstrated a favorable safety and tolerability profile in the multiple ascending dose trial with healthy volunteers, with no liver-related adverse events observed, laying a solid foundation for its further development in generalized anxiety disorder patients.
- Pharmacokinetic Advantages: The seven-day dosing regimen achieved therapeutic exposures of agomelatine that are projected to avoid liver enzyme elevations, thereby reducing or eliminating the need for liver function testing, significantly enhancing clinical applicability.
- Future Trial Plans: Seaport plans to initiate two parallel Phase 2 clinical trials in the second half of 2026, aimed at validating the efficacy and safety of GlyphAgo for patients with generalized anxiety disorder, potentially providing new treatment options for patients.
- Enhanced Bioavailability: In crossover trials, GlyphAgo showed a 6.8-fold increase in bioavailability compared to unmodified agomelatine, with 10-fold lower pharmacokinetic variability across different doses, further demonstrating its potential in clinical applications.
See More
Seaport Therapeutics Raises $260 Million in Successful IPO
- Successful IPO Financing: Seaport Therapeutics completed an upsized IPO in May 2026, raising $260 million in gross proceeds, which will support the company's operations into 2029, reflecting strong market confidence in its neuropsychiatric drug development.
- Clinical Trial Progress: New data from the Phase 1 trial of GlyphAgoTM indicate that a seven-day dosing regimen can achieve therapeutic exposures at doses projected to avoid liver enzyme elevations, potentially reducing or eliminating the need for liver function testing, thereby enhancing patient safety.
- New Board Member Appointment: Dr. Sharon Mates has been appointed to Seaport's Board of Directors; she previously served as the Co-Founder and CEO of Intra-Cellular Therapies, bringing extensive industry experience that is expected to drive the company's strategic development in the neuropsychiatry field.
- Increased R&D Spending: Research and development expenses for Q1 2026 were $21.4 million, significantly up from $10.5 million in Q1 2025, primarily due to accelerated clinical development of GlyphAlloTM and GlyphAgoTM, reflecting the company's ongoing commitment to new drug development.
See More
Latest Wall Street Rating Updates
- Vipshop Rating Upgrade: UBS upgraded Vipshop (VIPS) from Neutral to Buy, indicating that despite near-term growth pressures, the company's earnings quality and shareholder returns are more attractive, showcasing resilience in a competitive e-commerce landscape.
- Seaport Therapeutics Initiation: JPMorgan initiated coverage on Seaport Therapeutics (SPTX) with an Overweight rating and a price target of $42 for December 2027, reflecting bullish sentiment and highlighting the company's potential for growth in the biotech sector.
- Apple Price Target Increase: Bank of America raised its price target on Apple (AAPL) from $330 to $380, emphasizing significant opportunities in agentic AI, while reiterating a Buy rating, which underscores confidence in the company's future growth trajectory.
- Dave Inc. Initial Rating: UBS initiated coverage on Dave Inc. with a Buy rating and a price target of $300, suggesting that the market underestimates the durability of its high-velocity credit model and earnings growth trajectory, indicating strong future potential.
See More
Odyssey Therapeutics Raises $279 Million in Upsized IPO
- Upsized Fundraising: Odyssey Therapeutics successfully raised $279 million in its U.S. IPO by selling 15.5 million shares at $18 each, exceeding its expected range of $16 to $18, indicating strong market demand for biopharmaceutical companies.
- Market Recovery Context: The U.S. biotech IPO market has seen a revival in 2026, driven by policy shifts under President Trump and significant FDA reforms, prompting several biotech firms, including Seaport Therapeutics and Kailera Therapeutics, to go public recently.
- Research Focus: Odyssey is dedicated to developing treatments for autoimmune and inflammatory diseases, with its drug OD-001 currently in mid-stage trials for ulcerative colitis, highlighting its potential in the therapeutic landscape.
- Planned Use of Proceeds: The company intends to allocate the proceeds primarily for the clinical development of OD-001 and for general corporate purposes, further advancing its research efforts and laying the groundwork for future market expansion.
See More
Strong IPO Performance from Biotech Firms
- Biotech Financing Success: Hemab Therapeutics raised $302 million, achieving an $849 million market cap, focusing on antibody therapies for blood coagulation disorders, with its lead candidate poised for Phase 3 trials, which is expected to significantly enhance the company's competitive edge in the biopharmaceutical market.
- Pulmonary Fibrosis Treatment Progress: Avalyn Pharma also completed its IPO with $300 million raised and an $813 million market cap, concentrating on inhaled antifibrotic therapies for rare respiratory diseases, with key clinical data expected in mid-2027, potentially driving long-term growth for the company.
- Neuropsychiatric Drug Development: Seaport Therapeutics successfully raised $255 million, reaching a $1.1 billion market cap, focusing on treatments for neuropsychiatric disorders, with its lead program GlyphAllo in Phase 2b trials, which could further solidify its market position if successful.
- Mining Company IPO Underperformance: Silver Bow Mining raised $60 million with a market cap of $368 million, focusing on various mineral resources but has yet to generate revenue, with a 7% drop in stock price on its first day, indicating market caution regarding its prospects.
See More
Hemab and Seaport Shares Surge on Strong IPO Debuts
- Hemab's Debut Performance: Hemab Therapeutics priced its IPO at $18 per share, opening at $27, reflecting a ~50% increase, and reaching $29.68 by 1:30 PM ET, indicating strong market confidence in its bleeding disorder treatments.
- Seaport's Stock Surge: Seaport Therapeutics also priced its IPO at $18, opening at $21, a ~17% rise, and climbing to $22.51 by 1:30 PM ET, showcasing investor optimism regarding its neuropsychiatric drug development.
- Significant Fundraising: The two companies collectively raised over $550 million through upsized IPOs, with Hemab expecting $301.5 million and Seaport $254.9 million, providing robust funding for future R&D and market expansion.
- Positive Market Reaction: The successful listings of both companies not only highlight the vitality of the biotech sector but also reflect investor confidence in new drug development, particularly driven by positive clinical trial results, potentially attracting more attention to this field.
See More
